Amerigen Pharma signs agreement with AustarPharma
As per the agreement, AustarPharma will use its proprietary technologies for developing and manufacturing products for Amerigen to commercialize in the US and other territories. The terms of
China-based IMPACT Therapeutics and Pharmanovia have entered an exclusive licensing deal worth up to €423.5m ($488.3m), giving Pharmanovia rights to manufacture, develop, and commercialise senaparib in 66 countries.
Luminex’s xTAG GPP detects hemolytic-uremic syndrome (HUS) causing Shiga-like toxin producing E. coli strain (STEC), besides detecting common disease-causing gastrointestinal pathogens, including viruses, bacteria and parasites, such as
NKTR-181, a mu-opioid analgesic investigational drug candidate, was created using Nektar’s small molecule polymer conjugate technology. The Phase 1 study is assessing the pharmacokinetics, pharmacology, safety and efficacy